Evidence mapPaperPMID 38869934Full record

ArticleJMIR human factors2024

Assessing the Utility, Impact, and Adoption Challenges of an Artificial Intelligence-Enabled Prescription Advisory Tool for Type 2 Diabetes Management: Qualitative Study.

Sungwon Yoon, Hendra Goh, Phong Ching Lee, Hong Chang Tan, Ming Ming Teh, Dawn Shao Ting Lim, Ann Kwee, Chandran Suresh, David Carmody, Du Soon Swee and 5 more

Abstract read
In one paragraph

Article in JMIR human factors, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. AI-Driven Management of Type 2 Diabetes in China: Opportunities and Challenges.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sungwon YoonHealth Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0001-9458-6097
Hendra GohHealth Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0001-8886-6586
Phong Ching LeeDepartment of Endocrinology, Singapore General Hospital, Singapore, Singapore.ORCID 0000-0002-9446-2032
Hong Chang TanDepartment of Endocrinology, Singapore General Hospital, Singapore, Singapore.ORCID 0000-0001-8753-7158
Ming Ming TehDepartment of Endocrinology, Singapore General Hospital, Singapore, Singapore.ORCID 0000-0003-4300-0302
Dawn Shao Ting LimDepartment of Endocrinology, Singapore General Hospital, Singapore, Singapore.ORCID 0009-0007-9301-1970
Ann KweeDepartment of Endocrinology, Singapore General Hospital, Singapore, Singapore.ORCID 0000-0002-5700-2731
Chandran SureshDepartment of Endocrinology, Singapore General Hospital, Singapore, Singapore.ORCID 0000-0001-5944-4886
David CarmodyDepartment of Endocrinology, Singapore General Hospital, Singapore, Singapore.ORCID 0000-0002-8287-2560
Du Soon SweeDepartment of Endocrinology, Singapore General Hospital, Singapore, Singapore.ORCID 0000-0001-8162-6600
Sarah Ying Tse TanDepartment of Endocrinology, Singapore General Hospital, Singapore, Singapore.ORCID 0000-0001-5451-788X
Andy Jun-Wei WongDepartment of Endocrinology, Singapore General Hospital, Singapore, Singapore.ORCID 0000-0002-9148-8886
Charlotte Hui-Min ChooDepartment of Endocrinology, Singapore General Hospital, Singapore, Singapore.ORCID 0000-0003-2901-0723
Zongwen WeeDepartment of Endocrinology, Singapore General Hospital, Singapore, Singapore.ORCID 0000-0002-6066-3186
Yong Mong BeeDepartment of Endocrinology, Singapore General Hospital, Singapore, Singapore.ORCID 0000-0002-5482-2646

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clinical management of type 2 diabetes mellitus (T2DM) presents a significant challenge due to the constantly evolving clinical practice guidelines and growing array of drug classes available. Evidence suggests that artificial intelligence (AI)-enabled clinical decision support systems (CDSSs) have proven to be effective in assisting clinicians with informed decision-making. Despite the merits of AI-driven CDSSs, a significant research gap exists concerning the early-stage implementation and adoption of AI-enabled CDSSs in T2DM management.

objectiveThis study aimed to explore the perspectives of clinicians on the use and impact of the AI-enabled Prescription Advisory (APA) tool, developed using a multi-institution diabetes registry and implemented in specialist endocrinology clinics, and the challenges to its adoption and application.

methodsWe conducted focus group discussions using a semistructured interview guide with purposively selected endocrinologists from a tertiary hospital. The focus group discussions were audio-recorded and transcribed verbatim. Data were thematically analyzed.

resultsA total of 13 clinicians participated in 4 focus group discussions. Our findings suggest that the APA tool offered several useful features to assist clinicians in effectively managing T2DM. Specifically, clinicians viewed the AI-generated medication alterations as a good knowledge resource in supporting the clinician's decision-making on drug modifications at the point of care, particularly for patients with comorbidities. The complication risk prediction was seen as positively impacting patient care by facilitating early doctor-patient communication and initiating prompt clinical responses. However, the interpretability of the risk scores, concerns about overreliance and automation bias, and issues surrounding accountability and liability hindered the adoption of the APA tool in clinical practice.

conclusionsAlthough the APA tool holds great potential as a valuable resource for improving patient care, further efforts are required to address clinicians' concerns and improve the tool's acceptance and applicability in relevant contexts.

Indexed as

Artificial IntelligenceDiabetes Mellitus, Type 2Focus GroupsQualitative ResearchAdultDecision Support Systems, ClinicalFemaleHumansHypoglycemic AgentsMaleMiddle AgedHypoglycemic Agentsartificial intelligenceclinical decision support systemdiabetes managementendocrinologyhuman factors

Identifiers

PMID38869934
PMCPMC11211700

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.